hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06342388, orgStudyIdInfo id: 2024-0427, secondaryIdInfos id: A538500, type: OTHER, domain: UW- Madison, secondaryIdInfos id: Protocol Version 3/20/2024, type: OTHER, domain: UW- Madison, secondaryIdInfos id: SMPH/POP HEALTH SCI/POP HLTH, type: OTHER, domain: UW- Madison, briefTitle: Enrollment Barriers, Procedural Denials, and Loss of Medicaid Coverage, statusModule overallStatus: WITHDRAWN, startDateStruct date: 2024-07, primaryCompletionDateStruct date: 2026-03, completionDateStruct date: 2026-06, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: University of Wisconsin, Madison, class: OTHER, collaborators name: Covering Wisconsin, descriptionModule briefSummary: The goal of this study is to try new outreach methods to improve access to Medicaid for those who lost Medicaid for procedural reasons. The main questions it aims to answer are:1. How does a live phone call from a Navigator impact Medicaid enrollment among people who lost Medicaid coverage for procedural reasons?2. What is the effectiveness of outreach using a live call rather than a pre-recorded call?, conditionsModule conditions: No Medicaid Coverage, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 0, type: ACTUAL, armsInterventionsModule, outcomesModule primaryOutcomes measure: Number of people who successfully renew their Medicaid coverage within 3 months of receiving the live outbound call, secondaryOutcomes measure: Duration of coverage gaps, secondaryOutcomes measure: Number of people who successfully renew their Medicaid coverage within 6 months of receiving the live outbound call, secondaryOutcomes measure: Number of people who successfully renew their Medicaid coverage within 6 months of receiving the pre-recorded outbound call, eligibilityModule sex: ALL, minimumAge: 65 Years, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06342375, orgStudyIdInfo id: 2024-0434, secondaryIdInfos id: A538500, type: OTHER, domain: UW- Madison, secondaryIdInfos id: Protocol Version 3/20/2024, type: OTHER, domain: UW- Madison, secondaryIdInfos id: SMPH/POP HEALTH SCI/POP HLTH, type: OTHER, domain: UW- Madison, briefTitle: Enrollment Barriers, Procedural Denials, and Loss of Medicaid Coverage, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07, primaryCompletionDateStruct date: 2026-03, completionDateStruct date: 2026-06, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: University of Wisconsin, Madison, class: OTHER, collaborators name: Covering Wisconsin, descriptionModule briefSummary: The goal of this study is to try new outreach methods to improve access to Medicaid for those who lost Medicaid for procedural reasons. The main questions it aims to answer are:1. How does a live phone call from a Navigator impact Medicaid enrollment among people who lost Medicaid coverage for procedural reasons?2. What is the effectiveness of outreach using a live call rather than a pre-recorded call?, conditionsModule conditions: No Medicaid Coverage, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 425000, type: ESTIMATED, armsInterventionsModule interventions name: Outbound phone call, outcomesModule primaryOutcomes measure: Number of people who successfully renew their Medicaid coverage within 3 months of receiving the live outbound call, secondaryOutcomes measure: Duration of coverage gaps, secondaryOutcomes measure: Number of people who successfully renew their Medicaid coverage within 6 months of receiving the live outbound call, secondaryOutcomes measure: Number of people who successfully renew their Medicaid coverage within 6 months of receiving the pre-recorded outbound call, eligibilityModule sex: ALL, minimumAge: 50 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06342362, orgStudyIdInfo id: SICHN/IRB-001/2024, briefTitle: Magnesium Sulfate in Neonatal HIE", statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-02, primaryCompletionDateStruct date: 2024-10-02, completionDateStruct date: 2024-12-02, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Sindh Institute of Child Health and Neonatology, class: OTHER, descriptionModule briefSummary: The study will investigates the neuroprotective effects of intravenous magnesium sulfate in neonates with hypoxic-ischemic encephalopathy (HIE) at a Karachi tertiary care hospital. Using a randomized clinical trial design, the study targets term and near-term newborns with moderate to severe HIE. Data collection involves obtaining informed consent, preparing and administering magnesium sulfate, and assessing outcomes including mortality and morbidity. The study aims to provide insights into improving patient outcomes and clinical practice for neonatal HIE management., conditionsModule conditions: Neonates With HIE, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 102, type: ESTIMATED, armsInterventionsModule interventions name: Magnesium sulfate, interventions name: placebo or standard treatment), outcomesModule primaryOutcomes measure: Neuroprotective effects, eligibilityModule sex: ALL, minimumAge: 1 Day, maximumAge: 30 Days, stdAges: CHILD, contactsLocationsModule locations facility: SICHN, city: Karachi, state: Sindh, zip: 74201, country: Pakistan, contacts name: Naseem Ahmed, FCPS, role: CONTACT, phone: 03003145554, email: drnaseemkubar@gmail.com, geoPoint lat: 24.8608, lon: 67.0104, hasResults: False
protocolSection identificationModule nctId: NCT06342349, orgStudyIdInfo id: SIBP-V03-I, briefTitle: A Clinical Trial of Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) for Individuals Aged 6 Months and Above., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-31, primaryCompletionDateStruct date: 2024-12-30, completionDateStruct date: 2024-12-30, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Shanghai Institute Of Biological Products, class: INDUSTRY, collaborators name: Shaanxi Provincial Center for Disease Control and Prevention, descriptionModule briefSummary: To evaluate the safety of administering 1 or 2 doses of the quadrivalent influenza virus split vaccine (MDCK cells) (0.5ml/dose) in individuals aged 6 months and above., conditionsModule conditions: Influenza, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: This is a single center, randomized, double-blind, controlled phase I clinical trial., primaryPurpose: PREVENTION, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: Quadrivalent influenza virus split vaccine (MDCK cells), interventions name: Quadrivalent influenza virus split vaccine (Chicken embryo), interventions name: Phosphate buffer solution, outcomesModule primaryOutcomes measure: Solicited Adverse Events (AEs), primaryOutcomes measure: Unsolicited Adverse Events, primaryOutcomes measure: Serious Adverse Events (SAE), secondaryOutcomes measure: Seroconversion rate, secondaryOutcomes measure: Ratio of ≥1:40, secondaryOutcomes measure: Geometric mean increase (GMI), eligibilityModule sex: ALL, minimumAge: 6 Months, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06342336, orgStudyIdInfo id: HS-IT101ST01-I, briefTitle: HS-IT101 Injection in the Treatment of Advanced Solid Tumors, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-18, primaryCompletionDateStruct date: 2026-03-31, completionDateStruct date: 2028-03-31, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Qingdao Sino-Cell Biomedicine Co., Ltd., class: INDUSTRY, collaborators name: Cancer Institute and Hospital, Chinese Academy of Medical Sciences, collaborators name: The First Hospital of Jilin University, collaborators name: West China Hospital, descriptionModule briefSummary: Single-arm, open-label,interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocyte (TIL) infusion (HS-IT101) after lymphodepletion preparative with fludarabine and cyclophosphamide regimen, followed by IL-2, for the treatment of patients with advanced solid tumor., conditionsModule conditions: Solid Tumor, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 44, type: ESTIMATED, armsInterventionsModule interventions name: HS-IT101 Injection, outcomesModule primaryOutcomes measure: Adverse Events (AE), primaryOutcomes measure: Serious Adverse Events (SAE), secondaryOutcomes measure: Objective Response Rate (ORR), secondaryOutcomes measure: Time-to-response (TTR), secondaryOutcomes measure: Duration of Response (DOR), secondaryOutcomes measure: Disease Control Rate (DCR), secondaryOutcomes measure: Progression-Free-Survival (PFS), secondaryOutcomes measure: Overall Survival (OS), secondaryOutcomes measure: Lymphocyte subpopulation, secondaryOutcomes measure: TCR repertoire, eligibilityModule sex: ALL, minimumAge: 18 Days, maximumAge: 75 Days, stdAges: CHILD, contactsLocationsModule locations facility: Cancer Hospital, Chinese Academy of Medical Sciences, status: RECRUITING, city: Beijing, state: Beijing, zip: 100021, country: China, contacts name: Ning Li, MD, role: CONTACT, phone: 86-010-87788713, email: lining@cicams.ac.cn, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06342310, orgStudyIdInfo id: RE104-201-PPD, briefTitle: RE104 Safety and Efficacy Study in Postpartum Depression, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-05, completionDateStruct date: 2025-06, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Reunion Neuroscience Inc, class: INDUSTRY, descriptionModule briefSummary: The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms in participants with moderate-to-severe postpartum depression (PPD) as compared to active-placebo., conditionsModule conditions: Postpartum Depression, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 72, type: ESTIMATED, armsInterventionsModule interventions name: RE104 for Injection, outcomesModule primaryOutcomes measure: RE104 30 mg versus RE104 1.5 mg change from baseline in MADRS total score, secondaryOutcomes measure: RE104 30 mg versus RE104 1.5 mg change from baseline in MADRS total score, secondaryOutcomes measure: RE104 30 mg versus RE104 1.5 mg percentage of patients with MADRS response (≥ 50 percent reduction in score from baseline), secondaryOutcomes measure: RE104 30 mg versus RE104 1.5 mg percentage of patients with MADRS remission (score ≤ to 10), secondaryOutcomes measure: RE104 30 mg versus RE104 1.5 mg Clinical Global Impression-Improvement (CGI-I), secondaryOutcomes measure: RE104 30 mg versus RE104 1.5 mg change from baseline in CGI-Severity (CGI-S), secondaryOutcomes measure: RE104 30 mg versus RE104 1.5 mg changes in total score from baseline in Hamilton Anxiety Rating Scale (HAM-A), secondaryOutcomes measure: RE104 30 mg versus RE104 1.5 mg incidence of treatment-emergent adverse events (TEAEs) by frequency, severity and seriousness., eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06342297, orgStudyIdInfo id: OLL-1003043, briefTitle: Dermatoscopy Guided Resection for Skin Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-14, primaryCompletionDateStruct date: 2025-12-15, completionDateStruct date: 2026-01-14, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Region Örebro County, class: OTHER, descriptionModule briefSummary: In this randomizid controlled trial the aim is to use dermatoscopy in deciding the resection margin for patients with suspected or verified basal cell carcinoma or cutaneous squamous cell carcinoma. The outcome is radical/non radical resection of the lateral margins in the pathology report., conditionsModule conditions: Basal Cell Carcinoma, conditions: Cutaneous Squamous Cell Carcinoma, conditions: Surgical Margin, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 400, type: ESTIMATED, armsInterventionsModule interventions name: Dermatoscopy, outcomesModule primaryOutcomes measure: Pathology resection side margin (radical/not radical), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Örebro University Hospital, status: RECRUITING, city: Örebro, zip: 70375, country: Sweden, contacts name: Örebro U Hospital, role: CONTACT, phone: 0729655663, email: fredrik.landstrom@regionorebrolan.se, geoPoint lat: 59.27412, lon: 15.2066, hasResults: False
protocolSection identificationModule nctId: NCT06342284, orgStudyIdInfo id: NYPC ERC# 2021-030, briefTitle: Patient-Generated Health Data Collection During Chemoradiotherapy for Lung Cancer, acronym: PGHD, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-22, primaryCompletionDateStruct date: 2026-03-21, completionDateStruct date: 2031-03-21, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: The New York Proton Center, class: OTHER, descriptionModule briefSummary: This is an observational study involving the collection of patient-generated health data using an Apple Watch, a home pulse oximeter, and a smartphone during a course of proton beam radiotherapy for lung cancer. The study period over which this information is collected will range from the day of study enrollment until two weeks after radiotherapy completion. Subjects will complete a short satisfaction survey at the end of the study period. Other information that is collected as part of routine care for this patient population will be extracted from subjects' medical records during the study period and afterwards., conditionsModule conditions: Thoracic Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Proton Beam Radiation with or without concurrent chemotherapy, outcomesModule primaryOutcomes measure: Demonstrate the feasibility of patient-generated health data collection during thoracic proton beam radiotherapy for lung cancer, based on the quantity of data collected from the day of radiotherapy initiation to the day of radiotherapy completion., secondaryOutcomes measure: Demonstrate the face validity of physical activity and vital sign data collected in this trial by reviewing the distribution of values obtained for each measure quantitatively using descriptive statistics., otherOutcomes measure: Assess associations between radiotherapy treatment parameters, wearable device data, patient-reported outcomes, adverse events, and long-term clinical outcomes using inferential statistical analyses., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: New York Proton Center, status: RECRUITING, city: New York, state: New York, zip: 10035, country: United States, contacts name: Ryan Holder, BS, role: CONTACT, phone: 646-968-9055, email: rholder@nyproton.com, contacts name: Thomas Mistretta, MS, role: CONTACT, phone: 646-568-5675, email: tmistretta@nyproton.com, contacts name: Nitin Ohri, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Charles Simone, MD, role: SUB_INVESTIGATOR, contacts name: Annemarie Shepherd, MD, role: SUB_INVESTIGATOR, contacts name: Stanislav Lazarev, MD, role: SUB_INVESTIGATOR, contacts name: Alexandra Hanlon, PhD, role: SUB_INVESTIGATOR, geoPoint lat: 40.71427, lon: -74.00597, hasResults: False
protocolSection identificationModule nctId: NCT06342271, orgStudyIdInfo id: 24-2023, briefTitle: Effects of Nordic Walking and Free Walking on Arm Swing Parameters and Gait in Parkinson's Disease, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2025-03-30, completionDateStruct date: 2025-06-30, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: University of Talca, class: OTHER, descriptionModule briefSummary: People with Parkinson's Disease(PD) present a series of alterations such as muscle stiffness and motor slowing, which gradually affect the swinging movement of the arms and legs, altering the ability to walk, increasing the risk of falling, and reducing functionality. This implies a higher energy cost and a greater probability of developing freezing of the gait.Nordic walking (NW) is a form of physical exercise characterized by the use of walking poles, which could contribute positively to arm swing movement and, thus, gait.This clinical trial aims to compare Nordic Walking with free walking (FW) protocol training and investigate their effects on arm swing and gait parameters in people with PD.The study hypothesizes that NW training will reduce asymmetry and increase arm swing amplitudes during gait to a greater extent than FW. Also, improvements in arm swing could positively influence lower limb performance during regular gait, increasing gait speed, stride length, functional mobility, and quality of life.People with PD will complete 24 supervised NW or FW training sessions for 12 weeks. Both trainings will be identical in volume and intensity, the only difference will be the use of poles in the NW group. Blinded researchers will conduct evaluations at baseline (T0), post-intervention (T1), and in one-month follow-up (T2)., conditionsModule conditions: Parkinson Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 28, type: ESTIMATED, armsInterventionsModule interventions name: Nordic walking training, interventions name: Free Walking training, outcomesModule primaryOutcomes measure: Change in the amplitude of arm swing, primaryOutcomes measure: Change in the arm swing asymmetry, secondaryOutcomes measure: Change in the temporospatial measurements during walking including measurements of Gait speed [m/s] and step length [m]., secondaryOutcomes measure: Change in the functional mobility will be measured through the Timed up and go (TUG)., secondaryOutcomes measure: Change in the quality of life, eligibilityModule sex: ALL, minimumAge: 50 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06342245, orgStudyIdInfo id: 2023.568, briefTitle: Low-temperature Radiofrequency Coblation Micro-tenotomy for the Treatment of Achilles Tendinopathy, acronym: AT RCT, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-11, primaryCompletionDateStruct date: 2027-06-10, completionDateStruct date: 2027-06-11, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Chinese University of Hong Kong, class: OTHER, descriptionModule briefSummary: This is a prospective randomized, double-blinded, placebo-controlled superiority trial with two parallel groups and a 1:1 allocation ratio to investigate the effectiveness of radiofrequency coblation micro-tenotomy for patients with Achilles tendinopathy. All participants will be randomized into two groups: the intervention group (n=24; radiofrequency coblation micro-tenotomy + endoscopic Achilles debridement) and the control group (n=24; endoscopic Achilles debridement only). Adults (age \>18) with clinically diagnosed midportion Achilles tendinopathy will be recruited and scheduled for ultrasound screening. All participants will undergo a 12-week eccentric exercise program taught by a registered physiotherapist / athletic trainer. Undergo Endoscopic Achilles debridement and Radiofrequency coblation micro-tenotomy intervention. Criteria for discontinuing or modifying allocated interventions, Strategies to improve adherence to interventions, Relevant concomitant care permitted or prohibited during the trial and Provisions for post-trial care. Outocme measure will use VISA-A, pain scores, ultrasound measurement of thickness and vascularity, calf muscle strength, and ankle range of motion., conditionsModule conditions: Achilles Tendinopathy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: This is a multicentre prospective randomized, double-blinded, placebo-controlled superiority trial with two parallel groups and a 1:1 allocation ratio to investigate the effectiveness of radiofrequency coblation micro-tenotomy for patients with Achilles tendinopathy. All participants will be randomized into two groups: the intervention group (n=24; radiofrequency coblation micro-tenotomy + endoscopic Achilles debridement) and the control group (n=24; endoscopic Achilles debridement only).Investigators will obtain written consent from all participants before the commencement of this study., primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 48, type: ESTIMATED, armsInterventionsModule interventions name: Radiofrequency coblation micro-tenotomy, outcomesModule primaryOutcomes measure: Victorian Institute of Sports Assessment, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False